You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTolmetin
Accession NumberDB00500  (APRD01268)
TypeSmall Molecule
GroupsApproved
DescriptionA non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. [PubChem]
Structure
Thumb
Synonyms
1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid
1-Methyl-5-P-toluoylpyrrole-2-acetic acid
5-(P-Toluoyl)-1-methylpyrrole-2-acetic acid
Tolmetin
Tolmetina
Tolmétine
Tolmetino
Tolmetinum
External Identifiers
  • McN 2559
  • McN 2559-21-98
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-tolmetin Capsules 400mgCapsule400 mgOralNovopharm Limited1994-12-312005-08-10Canada
Tolectin 200 Tab 200mgTablet245 mgOralMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1976-12-312002-08-02Canada
Tolectin 400 Cap 400mgCapsule400 mgOralMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1980-12-312002-08-02Canada
Tolectin Tab 600mgTablet600 mgOralJanssen Inc1987-12-312006-02-27Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tolmetin SodiumCapsule400 mg/1OralTeva Pharmaceuticals USA Inc2012-07-26Not applicableUs
Tolmetin SodiumTablet200 mg/1OralMutual Pharmaceutical Company, Inc.2009-09-04Not applicableUs
Tolmetin SodiumTablet, film coated600 mg/1OralMylan Pharmaceuticals Inc.1994-08-30Not applicableUs
Tolmetin SodiumCapsule400 mg/1OralMutual Pharmaceutical Company, Inc.2009-09-04Not applicableUs
Tolmetin SodiumCapsule400 mg/1OralMylan Pharmaceuticals Inc.1993-05-27Not applicableUs
Tolmetin SodiumTablet, film coated600 mg/1OralSTAT Rx USA LLC2009-11-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
TolectinTeva
Tolectin DSTeva
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tolmetin sodium
64490-92-2
Thumb
  • InChI Key: QGUALMNFRILWRA-UHFFFAOYSA-M
  • Monoisotopic Mass: 279.087137994
  • Average Mass: 279.2663
DBSALT000496
Categories
UNIID8K2JPN18B
CAS number26171-23-3
WeightAverage: 257.2845
Monoisotopic: 257.105193351
Chemical FormulaC15H15NO3
InChI KeyUPSPUYADGBWSHF-UHFFFAOYSA-N
InChI
InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
IUPAC Name
2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetic acid
SMILES
CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1
Pharmacology
IndicationFor the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management. Also for treatment of juvenile rheumatoid arthritis.
Structured Indications
PharmacodynamicsTolmetin is a nonsteroidal anti-inflammatory agent. Studies in animals have shown tolmetin to possess anti-inflammatory, analgesic and antipyretic activity. In the rat, tolmetin prevents the development of experimentally induced polyarthritis and also decreases established inflammation. In patients with either rheumatoid arthritis or osteaoarthritis, tolmetin is as effective as aspirin and indomethacin in controlling disease activity, but the frequency of the milder gastrointestinal adverse effects and tinnitus was less than in aspirin-treated patients, and the incidence of central nervous system adverse effects was less than in indomethacin-treated patients. In patients with juvenile rheumatoid arthritis, tolmetin is as effective as aspirin in controlling disease activity, with a similar incidence of adverse reactions. tolmetin has produced additional therapeutic benefit when added to a regimen of gold salts and, to a lesser extent, with corticosteroids. Tolmetin should not be used in conjunction with salicylates since greater benefit from the combination is not likely, but the potential for adverse reactions is increased.
Mechanism of actionThe mode of action of tolmetin is not known. However, studies in laboratory animals and man have demonstrated that the anti-inflammatory action of tolmetin is not due to pituitary-adrenal stimulation. Tolmetin inhibits prostaglandin synthetase in vitro and lowers the plasma level of prostaglandin E in man. This reduction in prostaglandin synthesis may be responsible for the anti-inflammatory action. Tolmetin does not appear to alter the course of the underlying disease in man.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Related Articles
AbsorptionRapidly and almost completely absorbed with peak plasma levels being reached within 30-60 minutes after an oral therapeutic dose.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Essentially all of the administered dose is recovered in the urine in 24 hours either as an inactive oxidative metabolite or as conjugates of tolmetin.

SubstrateEnzymesProduct
Tolmetin
Not Available
Tolmetin glucuronideDetails
Route of eliminationNot Available
Half lifeBiphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Tolmetin Action PathwayDrug actionSMP00704
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tolmetin is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Tolmetin is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Tolmetin is combined with 5-androstenedione.Experimental, Illicit
AbciximabTolmetin may increase the anticoagulant activities of Abciximab.Approved
AcebutololTolmetin may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Aceclofenac.Approved
AcenocoumarolTolmetin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinTolmetin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tolmetin.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alendronic acid.Approved
AliskirenTolmetin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololTolmetin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tolmetin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Amcinonide.Approved
AmikacinTolmetin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideTolmetin may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinTolmetin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodTolmetin may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Tolmetin is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Anisodamine.Investigational
annamycinTolmetin may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Antipyrine.Approved
Antithrombin III humanTolmetin may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Tolmetin may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanTolmetin may increase the anticoagulant activities of Apixaban.Approved
ApramycinTolmetin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Tolmetin is combined with Apremilast.Approved, Investigational
ArbekacinTolmetin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinTolmetin may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanTolmetin may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTolmetin may decrease the antihypertensive activities of Arotinolol.Approved
AtenololTolmetin may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolmetin.Approved
BalsalazideTolmetin may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminTolmetin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTolmetin may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tolmetin.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolmetin.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tolmetin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Betamethasone.Approved, Vet Approved
BetaxololTolmetin may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Betulinic Acid.Investigational
BevantololTolmetin may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tolmetin.Approved, Investigational
BisoprololTolmetin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTolmetin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTolmetin may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bucillamine.Investigational
BucindololTolmetin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Budesonide.Approved
BufuralolTolmetin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideTolmetin may decrease the diuretic activities of Bumetanide.Approved
BupranololTolmetin may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolmetin.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tolmetin.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tolmetin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tolmetin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololTolmetin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTolmetin may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Celecoxib.Approved, Investigational
CeliprololTolmetin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTolmetin may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolmetin.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tolmetin.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolmetin.Approved
CinoxacinTolmetin may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinTolmetin may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidTolmetin may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tolmetin.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Tolmetin is combined with Curcumin.Investigational
CyclosporineTolmetin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Tolmetin is combined with D-Limonene.Investigational
Dabigatran etexilateTolmetin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTolmetin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTolmetin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinTolmetin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Tolmetin is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Tolmetin is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinTolmetin may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tolmetin.Approved
DextranTolmetin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Tolmetin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Tolmetin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Tolmetin may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tolmetin.Approved, Vet Approved
DicoumarolTolmetin may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Tolmetin is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tolmetin.Approved
DihydrostreptomycinTolmetin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tolmetin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tolmetin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tolmetin.Approved
DoxorubicinTolmetin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTolmetin may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Tolmetin is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ebselen.Investigational
Edetic AcidTolmetin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTolmetin may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tolmetin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolmetin.Approved
EnoxacinTolmetin may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinTolmetin may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Tolmetin is combined with Epirizole.Approved
EpirubicinTolmetin may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneTolmetin may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolmetin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolmetin.Approved
EquileninThe risk or severity of adverse effects can be increased when Tolmetin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Equilin.Approved
EsmololTolmetin may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Estrone sulfate.Approved
Etacrynic acidTolmetin may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tolmetin.Approved, Investigational
Ethyl biscoumacetateTolmetin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Tolmetin is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tolmetin.Vet Approved
FleroxacinTolmetin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tolmetin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fludrocortisone.Approved
FluindioneTolmetin may increase the anticoagulant activities of Fluindione.Investigational
FlumequineTolmetin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tolmetin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tolmetin.Approved, Nutraceutical, Vet Approved
FondaparinuxTolmetin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTolmetin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tolmetin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tolmetin.Approved
FramycetinTolmetin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideTolmetin may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateTolmetin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTolmetin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTolmetin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tolmetin.Approved, Withdrawn
GemifloxacinTolmetin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTolmetin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTolmetin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATolmetin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinTolmetin may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Tolmetin is combined with HE3286.Investigational
HeparinTolmetin may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Higenamine.Investigational
HirulogTolmetin may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Tolmetin is combined with HMPL-004.Investigational
HydralazineTolmetin may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolmetin.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tolmetin.Approved
Hygromycin BTolmetin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Tolmetin is combined with Icatibant.Approved
IdarubicinTolmetin may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxTolmetin may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolmetin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolmetin.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolmetin.Approved
IndenololTolmetin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolmetin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Indoprofen.Withdrawn
INNO-206Tolmetin may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolmetin.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tolmetin is combined with Istaroxime.Investigational
KanamycinTolmetin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tolmetin.Approved
LabetalolTolmetin may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tolmetin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Leflunomide.Approved, Investigational
LepirudinTolmetin may increase the anticoagulant activities of Lepirudin.Approved
LevobunololTolmetin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTolmetin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tolmetin.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tolmetin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Tolmetin.Approved
LomefloxacinTolmetin may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tolmetin.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tolmetin.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tolmetin.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tolmetin.Approved
ME-609The risk or severity of adverse effects can be increased when Tolmetin is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mefenamic acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meloxicam.Approved, Vet Approved
MesalazineTolmetin may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Tolmetin is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tolmetin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolmetin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTolmetin may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolmetin.Approved
MetoprololTolmetin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTolmetin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tolmetin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolmetin.Approved
MometasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tolmetin.Approved
MoxifloxacinTolmetin may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nabumetone.Approved
NadololTolmetin may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTolmetin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTolmetin may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Naftifine.Approved
Nalidixic AcidTolmetin may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Tolmetin is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Tolmetin is combined with NCX 4016.Investigational
NeamineTolmetin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinTolmetin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTolmetin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nepafenac.Approved
NetilmicinTolmetin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nitroaspirin.Investigational
NorfloxacinTolmetin may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinTolmetin may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolmetin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Olopatadine.Approved
OlsalazineTolmetin may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Tolmetin.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Orgotein.Vet Approved
OtamixabanTolmetin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxaprozin.Approved
OxprenololTolmetin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Parecoxib.Approved
ParomomycinTolmetin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinTolmetin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTolmetin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTolmetin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateTolmetin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tolmetin.Approved
PhenindioneTolmetin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonTolmetin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolmetin.Approved, Investigational
PindololTolmetin may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinTolmetin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideTolmetin may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Piroxicam.Approved, Investigational
PlicamycinTolmetin may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tolmetin.Approved
PractololTolmetin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tolmetin.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Tolmetin can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Propacetamol.Approved
PropranololTolmetin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tolmetin.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Tolmetin.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tolmetin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tolmetin.Vet Approved
Protein CTolmetin may increase the anticoagulant activities of Protein C.Approved
Protein S humanTolmetin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTolmetin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTolmetin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Tolmetin is combined with PTC299.Investigational
PuromycinTolmetin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolmetin.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tolmetin.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tolmetin.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tolmetin.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Resveratrol.Experimental, Investigational
ReviparinTolmetin may increase the anticoagulant activities of Reviparin.Approved
RibostamycinTolmetin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Risedronate.Approved, Investigational
RivaroxabanTolmetin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinTolmetin may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tolmetin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolmetin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tolmetin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Tolmetin is combined with Seratrodast.Approved, Investigational
SisomicinTolmetin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolTolmetin may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTolmetin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTolmetin may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinTolmetin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tolmetin.Approved
SpironolactoneTolmetin may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Tolmetin is combined with SRT501.Investigational
StreptomycinTolmetin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTolmetin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineTolmetin may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Sulindac.Approved
SulodexideTolmetin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tolmetin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Suprofen.Approved, Withdrawn
TacrolimusTolmetin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tolmetin.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tolmetin.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tolmetin.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolmetin.Approved, Investigational
TemafloxacinTolmetin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Tolmetin.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tolmetin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tiaprofenic acid.Approved
TiludronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tiludronate.Approved, Vet Approved
TimololTolmetin may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tixocortol.Approved
TobramycinTolmetin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tolfenamic Acid.Approved
TorasemideTolmetin may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tolmetin.Approved
TranilastThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolmetin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolmetin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTolmetin may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolmetin.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Trisalicylate-choline.Approved
TrovafloxacinTolmetin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tolmetin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinTolmetin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolmetin.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tolmetin.Approved
WarfarinTolmetin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTolmetin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Tolmetin may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zileuton.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zomepirac.Withdrawn
ZorubicinTolmetin may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AB03M02AA21
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (77.4 KB)
MSDSDownload (44.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9752
Blood Brain Barrier+0.8387
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.7277
P-glycoprotein inhibitor INon-inhibitor0.9062
P-glycoprotein inhibitor IINon-inhibitor0.9542
Renal organic cation transporterNon-inhibitor0.7999
CYP450 2C9 substrateNon-substrate0.7091
CYP450 2D6 substrateNon-substrate0.7867
CYP450 3A4 substrateNon-substrate0.6233
CYP450 1A2 substrateNon-inhibitor0.9159
CYP450 2C9 inhibitorNon-inhibitor0.9353
CYP450 2D6 inhibitorNon-inhibitor0.9449
CYP450 2C19 inhibitorNon-inhibitor0.9389
CYP450 3A4 inhibitorNon-inhibitor0.9563
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9346
Ames testNon AMES toxic0.8887
CarcinogenicityNon-carcinogens0.8992
BiodegradationReady biodegradable0.5
Rat acute toxicity2.9129 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9535
hERG inhibition (predictor II)Non-inhibitor0.9545
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Actavis elizabeth llc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral400 mg
TabletOral245 mg
TabletOral600 mg
CapsuleOral400 mg/1
TabletOral200 mg/1
Tablet, film coatedOral600 mg/1
Prices
Unit descriptionCostUnit
Tolectin 600 mg tablet2.43USD tablet
Tolmetin sodium 600 mg tablet2.06USD tablet
Tolmetin Sodium 400 mg capsule1.77USD capsule
Tolmetin sodium 200 mg tablet0.77USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point156 dec °CPhysProp
water solubility222 mg/LNot Available
logP2.79SANGSTER (1993)
pKa3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.131 mg/mLALOGPS
logP2.81ALOGPS
logP2.73ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.96ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity72.39 m3·mol-1ChemAxon
Polarizability27.67 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.07 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetophenones. These are organic compounds containing the acetophenone structure.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAcetophenones
Direct ParentAcetophenones
Alternative Parents
Substituents
  • Acetophenone
  • Aryl ketone
  • Benzoyl
  • Toluene
  • Substituted pyrrole
  • N-methylpyrrole
  • Heteroaromatic compound
  • Pyrrole
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Burdan F, Szumilo J, Klepacz R, Dudka J, Korobowicz A, Tokarska E, Cendrowska-Pinkosz M, Madej B, Klepacz L: Gastrointestinal and hepatic toxicity of selective and non-selective cyclooxygenase-2 inhibitors in pregnant and non-pregnant rats. Pharmacol Res. 2004 Nov;50(5):533-43. [PubMed:15458776 ]
  2. Capasso A, Sorrentino L: Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Eur J Pharmacol. 1997 Jul 9;330(2-3):199-204. [PubMed:9253954 ]
  3. Kirkova M, Alexandova A, Kesiova M, Todorov S: In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs. Auton Autacoid Pharmacol. 2007 Apr;27(2):99-104. [PubMed:17391279 ]
  4. Kennedy JH, Korn N, Thurston RJ: Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility. Reprod Biol Endocrinol. 2003 Oct 9;1:74. [PubMed:14613550 ]
  5. Capasso A: Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology. 1999 Jun;38(6):871-7. [PubMed:10465690 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Capasso A, Sorrentino L: Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Eur J Pharmacol. 1997 Jul 9;330(2-3):199-204. [PubMed:9253954 ]
  2. Kennedy JH, Korn N, Thurston RJ: Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility. Reprod Biol Endocrinol. 2003 Oct 9;1:74. [PubMed:14613550 ]
  3. Capasso A: Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology. 1999 Jun;38(6):871-7. [PubMed:10465690 ]
  4. Burdan F, Szumilo J, Marzec B, Klepacz R, Dudka J: Skeletal developmental effects of selective and nonselective cyclooxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL:(WI)WUBR rats. Toxicology. 2005 Dec 15;216(2-3):204-23. Epub 2005 Sep 22. [PubMed:16182428 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Tryptophan 2,3-dioxygenase activity
Specific Function:
Incorporates oxygen into the indole moiety of tryptophan. Has a broad specificity towards tryptamine and derivatives including D- and L-tryptophan, 5-hydroxytryptophan and serotonin (By similarity).
Gene Name:
TDO2
Uniprot ID:
P48775
Molecular Weight:
47871.215 Da
References
  1. Dairam A, Antunes EM, Saravanan KS, Daya S: Non-steroidal anti-inflammatory agents, tolmetin and sulindac, inhibit liver tryptophan 2,3-dioxygenase activity and alter brain neurotransmitter levels. Life Sci. 2006 Nov 10;79(24):2269-74. Epub 2006 Aug 1. [PubMed:16952380 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Anderson R, Oosthuizen R, Grabow G: Prevention of peroxidase mediated inhibition of neutrophil motility and lymphocyte transformation by levamisole, OMPI, sodium aurothiomalate, indomethacin and tolmetin in vitro. Int J Immunopharmacol. 1981;3(2):123-32. [PubMed:6266970 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23